Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.
Launched by UCB PHARMA · Jan 12, 2007
Trial Information
Current as of May 04, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of epilepsy
- • Subject having at least 1 seizure (any type) during the 3 weeks before first visit
- • Stable dosing of 1-3 concomitant antiepileptic drugs
- Exclusion Criteria:
- • Pregnant or nursing females
- • Concomitant use of Levetiracetam
- • Epilepsy secondary to a Progressive cerebral disease/tumor or other neurodegenerative disease
- • History of status epilepticus
- • Clinically significant acute or chronic illness, underlying disease or medication condition
- • History of suicide attempt
About Ucb Pharma
UCB Pharma is a global biopharmaceutical company dedicated to discovering and delivering innovative treatments for severe diseases in neurology and immunology. With a strong focus on research and development, UCB leverages cutting-edge science and technology to advance its pipeline of therapies aimed at improving the quality of life for patients. Committed to collaboration and patient-centricity, UCB engages with healthcare professionals and patient communities to ensure its clinical trials address unmet medical needs and contribute to the advancement of healthcare solutions worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gulf Breeze, Florida, United States
Miami, Florida, United States
Wellington, Florida, United States
Boston, Massachusetts, United States
Saint Paul, Minnesota, United States
Chesterfield, Missouri, United States
Buffalo, New York, United States
Rochester, New York, United States
Cincinnati, Ohio, United States
Pittsburgh, Pennsylvania, United States
Nashville, Tennessee, United States
Houston, Texas, United States
Brussels, , Belgium
Brussels, , Belgium
Leuven, , Belgium
Hradec Kralove, , Czechia
Ostrava Porubo, , Czechia
Praha 4, , Czechia
Aguascalientes, , Mexico
Chihuahua, , Mexico
Ciuliacan, , Mexico
Guadalajara, , Mexico
Mexico D.F., , Mexico
Monterrey, , Mexico
San Luis Potosi, , Mexico
Bialystok, , Poland
Gdansk, , Poland
Kielce, , Poland
Krakow, , Poland
Poznan, , Poland
Rzeszow, , Poland
Szczecin, , Poland
Wroclaw, , Poland
Barcelona, , Spain
Madrid, , Spain
Palma De Mallorca, , Spain
Santander, , Spain
Valencia, , Spain
Zaragoza, , Spain
Patients applied
Trial Officials
UCB Clinical Trial Call Center
Study Director
+1 877 822 9493 (UCB)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials